简体
  • 简体中文
  • 繁体中文

热门资讯> 正文

CVRx股价上涨,CMS纳入Barostim植入手术

2025-07-17 04:08

  • CVRx (NASDAQ:CVRX) saw a 17% increase in its shares following the announcement that Centers for Medicare and Medicaid Services (CMS) has proposed to include the Barostim implant procedure.
  • The procedure is included under the New Technology Ambulatory Payment Classification 1580, which would provide around $45,000 for outpatient procedures.
  • Additionally, CMS is seeking feedback on the potential need for a Level 6 Neurostimulator APC.
  • This proposal comes after two other favorable updates regarding reimbursement rates in the past nine months.

风险及免责提示:以上内容仅代表作者的个人立场和观点,不代表华盛的任何立场,华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前,应结合自身情况,考虑投资产品的风险。必要时,请咨询专业投资顾问的意见。华盛不提供任何投资建议,对此亦不做任何承诺和保证。